Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9Y535

UPID:
RPC8_HUMAN

ALTERNATIVE NAMES:
DNA-directed RNA polymerase III subunit H; RNA polymerase III subunit 22.9 kDa subunit

ALTERNATIVE UPACC:
Q9Y535; B0QYH9; Q5M7Y8; Q96AE3; Q9BY95

BACKGROUND:
The protein DNA-directed RNA polymerase III subunit RPC8, alternatively named RNA polymerase III subunit 22.9 kDa subunit, is integral to the transcription process, converting DNA into RNA. It synthesizes essential small RNAs and plays a key role in the body's defense mechanism against intracellular pathogens by acting as a DNA sensor in the innate immune system.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of DNA-directed RNA polymerase III subunit RPC8 offers a promising avenue for developing new therapeutic approaches. Its critical role in immune surveillance and response to pathogenic DNA makes it a compelling target for drug discovery, aiming to enhance or modulate the immune system.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.